Litigation Details for Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2018)

Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2018)

Docket	1:18-cv-01900	Date Filed	2018-11-30
Court	District Court, D. Delaware	Date Terminated	2020-10-07
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To	Christopher J. Burke
Patents	10,004,729; 9,682,075; 9,737,530; 9,968,598
Link to Docket	External link to docket

Details for Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-11-30				External link to document
2018-11-29	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,968,598; 10,004,729. (ceg) (Entered…2018 7 October 2020 1:18-cv-01900 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Collegium Pharmaceutical v. Teva Pharmaceuticals: Xtampza ER Patent Litigation Summary

Last updated: August 17, 2026

Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc., No. 1:18-cv-01900, was an ANDA patent case concerning Teva’s proposed generic version of Xtampza ER, Collegium’s extended-release oxycodone product. Collegium asserted patents covering the product’s abuse-deterrent formulation and controlled-release technology. The case was resolved through a settlement rather than a publicly reported final trial judgment.

What drug and patents were involved in Collegium v. Teva?

The dispute concerned Xtampza ER, an extended-release oxycodone product approved by the U.S. Food and Drug Administration in June 2016. Collegium markets Xtampza ER using its DETERx technology, which combines oxycodone with inactive ingredients designed to reduce drug release when the dosage form is crushed or manipulated.

Teva submitted an abbreviated new drug application seeking approval to market generic oxycodone extended-release capsules. Collegium treated Teva’s ANDA filing as a Paragraph IV certification against patents listed in the FDA Orange Book.

The principal patents associated with the litigation were:

Patent	General subject matter	Relevance
U.S. Patent No. 9,693,961	Abuse-deterrent controlled-release oxycodone dosage forms	Asserted against Teva’s proposed product
U.S. Patent No. 9,737,530	Controlled-release oxycodone formulations and dosage forms	Asserted against Teva’s proposed product
Related Xtampza ER patents	Formulation, manufacturing and use claims	Created additional generic-entry barriers

The patents generally claim combinations of oxycodone and hydrophobic or waxy excipients that control drug release and make the dosage form more resistant to physical and chemical manipulation. The commercial value of the patents lies in the formulation architecture rather than the active pharmaceutical ingredient, oxycodone, which is long off patent.

What was the procedural history of the case?

Collegium filed the action in the U.S. District Court for the District of Delaware after receiving notice of Teva’s Paragraph IV certifications. The case was assigned civil action number 1:18-cv-01900.

The litigation followed the standard Hatch-Waxman sequence:

1. Teva filed an ANDA for generic Xtampza ER.
2. Teva served Collegium with a Paragraph IV notice letter.
3. Collegium filed an infringement action within the statutory 45-day period.
4. FDA approval of Teva’s ANDA was subject to the 30-month stay under the Hatch-Waxman Act.
5. The parties litigated patent validity, infringement and the scope of Teva’s proposed product.
6. The case ended through a settlement and dismissal rather than a reported merits decision.

The public record does not reflect a final adjudication holding the asserted patents invalid or unenforceable. That distinction matters. The absence of a final invalidity judgment preserved Collegium’s ability to rely on the Xtampza ER patent estate against other ANDA filers.

What were Collegium’s infringement theories?

Collegium’s infringement case was based on the composition and release characteristics of Teva’s proposed generic product. The asserted claims focused on technical features associated with Xtampza ER, including:

• Oxycodone or an oxycodone salt as the active ingredient.
• A hydrophobic or wax-based matrix.
• Controlled release over an extended dosing interval.
• Resistance to extraction, crushing or other forms of abuse.
• Specific physical and chemical characteristics of the dosage form.

In an ANDA case, infringement analysis is based on the product described in the ANDA, not necessarily the product ultimately sold. Collegium therefore had to show that Teva’s proposed manufacturing process and dosage form met the limitations of the asserted claims.

The central technical issue was likely whether Teva’s formulation used the claimed combination of excipients and release-control properties. A generic applicant can avoid infringement by changing the formulation, but those changes must remain within FDA approval requirements and must preserve the product’s bioequivalence.

What defenses did Teva raise?

Teva’s Paragraph IV position would have placed the following defenses at issue:

Invalidity

Teva could challenge the asserted claims under:

• Obviousness under 35 U.S.C. § 103.
• Lack of written description under 35 U.S.C. § 112.
• Lack of enablement under 35 U.S.C. § 112.
• Lack of utility or indefiniteness where relevant.

Obviousness was the most commercially significant defense. Teva could argue that extended-release oxycodone products, abuse-deterrent matrices and hydrophobic excipients were known in the prior art, making the claimed formulation an obvious combination.

Collegium’s response would center on formulation-specific technical results, including resistance to manipulation, controlled dissolution and the ability to maintain oxycodone release characteristics after physical tampering. For pharmaceutical formulation patents, evidence of unexpected results can materially affect the obviousness analysis.

Noninfringement

Teva could contend that its proposed product did not contain one or more required claim elements. The most likely noninfringement arguments would concern:

• The type or amount of wax or hydrophobic excipient.
• The structure of the release-control matrix.
• The dosage form’s abuse-deterrent properties.
• Dissolution or extraction performance.
• The manufacturing sequence used to produce the dosage form.

Claim construction

Claim construction would have been important because formulation claims often turn on technical terms such as “matrix,” “hydrophobic,” “controlled release,” “abuse deterrent” and measured dissolution parameters. A narrow construction could have reduced Collegium’s infringement reach. A broader construction could have increased the likelihood that Teva’s ANDA product fell within the claims but also could have exposed the claims to more prior art.

What was the outcome of Collegium v. Teva?

The case was resolved by settlement and dismissed. Publicly available company disclosures and docket materials do not indicate a final trial verdict invalidating the asserted Xtampza ER patents or finding Teva liable after trial.

The settlement structure in an ANDA case typically addresses:

• The date Teva may launch its generic product.
• Whether Teva may launch earlier upon a triggering event.
• Rights relating to authorized generic competition.
• Allocation of patent and regulatory risks.
• Dismissal of the infringement claims.
• Confidential commercial terms.

The precise economic terms and any launch-date provisions should be read from the settlement-related filings and Collegium’s SEC disclosures. A case dismissal alone does not establish that Teva’s ANDA product was noninfringing or that the asserted patents were invalid.

When could Teva launch a generic version of Xtampza ER?

A settlement can permit a generic launch before the expiration of all Orange Book-listed patents if the parties agree to an authorized launch date. That date may be earlier than the latest patent expiration but later than the earliest possible date based solely on a successful Paragraph IV challenge.

The commercial impact depends on four dates:

Date category	Effect
FDA approval date	Determines when Teva can receive final regulatory approval
30-month stay expiration	Removes the statutory litigation-based approval block unless otherwise extended
Settlement launch date	Controls the agreed commercial entry date
Last enforceable patent expiration	Sets the outer patent barrier absent an earlier launch agreement

Teva’s settlement entry date, rather than the mere existence of an ANDA, is the key competitive variable. If the agreement permits launch before all formulation patents expire, Teva could enter under a negotiated license. If the launch date is after the principal patents expire, the settlement primarily removes litigation uncertainty without materially accelerating competition.

What is the Orange Book status of Xtampza ER?

Xtampza ER is a small-molecule prescription drug, not a biologic. Biosimilar rules do not apply. Any competing product would generally proceed through the ANDA pathway as a generic drug, assuming the applicant can demonstrate pharmaceutical equivalence and bioequivalence.

The Orange Book analysis is more complex than a simple active-ingredient patent review because Xtampza ER’s protection is formulation-driven. Relevant categories include:

• Drug-product patents.
• Formulation patents.
• Method-of-use patents.
• Potential manufacturing-related patents, where listed or asserted separately.

Orange Book-listed patents can trigger Paragraph IV litigation and the 30-month stay. Unlisted patents can still support infringement litigation, but they do not necessarily generate the same Orange Book-based regulatory consequences.

How strong is Collegium’s Xtampza ER patent estate?

Collegium’s patent position is stronger against straightforward copies of the DETERx formulation than against materially redesigned products.

Strengths

The estate has several commercial advantages:

• It protects formulation technology rather than only oxycodone.
• It can cover physical properties and release behavior that are important to bioequivalence.
• It creates technical design-around costs for generic manufacturers.
• The formulation is linked to abuse-deterrent labeling and product differentiation.
• A generic applicant must satisfy both FDA bioequivalence requirements and patent constraints.

Weaknesses

The estate also has limitations:

• Oxycodone is an old active ingredient with extensive prior art.
• Extended-release matrices and abuse-deterrent excipients are established formulation concepts.
• Broad claims may face obviousness challenges.
• Narrow claims may be easier to design around.
• Patent expiration dates limit the duration of the commercial moat.
• A formulation patent does not prevent all extended-release oxycodone products if they use a different technology.

The strongest claims are those tied to specific, difficult-to-replicate combinations of excipients, processing conditions and dissolution results. Claims defined only by broad functional language face greater validity and construction risk.

What generic entry risks exist for Xtampza ER?

The principal entry risks are formulation patents, settlement-based launch rights and the possibility that multiple generic applicants obtain approval around the same time.

A generic launch could produce:

• Rapid price erosion.
• Pharmacy substitution.
• Payer-mandated switching.
• Loss of premium pricing associated with the branded product.
• Reduced value of the DETERx differentiation.
• Increased litigation involving later ANDA filers.

The risk is lower if the settlement gives Teva a late launch date and if Collegium retains enforceable patents against other applicants. The risk is higher if Teva receives an early licensed entry right or if another applicant successfully invalidates a key patent.

Which companies could challenge Xtampza ER exclusivity?

Teva was one of the identified ANDA challengers. Other generic companies may pursue Xtampza ER through their own ANDAs, Paragraph IV certifications or product designs that attempt to avoid the asserted claims.

The competitive field should be evaluated by:

• Number of ANDAs filed.
• Whether each applicant filed Paragraph IV certifications.
• Whether Collegium sued within the statutory period.
• Whether each applicant has a first-filer position.
• Whether settlements grant staggered or simultaneous launch rights.
• Whether the applicant’s formulation is materially different from Teva’s.

The first approved generic does not always establish permanent market control. Additional approved ANDA products can enter after separate litigation or settlements.

How does Xtampza ER compare with competing extended-release opioids?

Xtampza ER differs from conventional extended-release oxycodone products because its commercial positioning depends on abuse-deterrent formulation technology.

Product category	Active ingredient	Protection profile	Competitive issue
Xtampza ER	Oxycodone	Formulation and abuse-deterrence patents	Generic formulation replication
Conventional oxycodone ER	Oxycodone	Generally mature product technology	Price competition
OxyContin	Oxycodone	Historical abuse-deterrent formulation estate	Established generic competition
Other extended-release opioids	Various opioids	Product-specific patents	Clinical substitution and payer policy

Xtampza ER’s patent value is therefore tied to both legal exclusivity and product differentiation. If generic manufacturers cannot reproduce the same abuse-deterrent profile, Collegium may retain some clinical and commercial segmentation after initial generic entry. If a generic obtains an equivalent label and comparable formulation profile, substitution pressure is more direct.

What is the revenue exposure from this litigation?

Xtampza ER is a branded product with revenue exposure concentrated in the period before generic entry. The settlement reduced binary litigation risk but also potentially fixed the timing of future competition.

Revenue impact depends on:

• Xtampza ER net sales before entry.
• The agreed Teva launch date.
• Whether Teva launches alone or with other generics.
• The depth of generic discounts.
• Payer substitution rules.
• Collegium’s ability to retain prescriptions through abuse-deterrent positioning.
• Whether Collegium licenses or launches an authorized generic.

In a single-generic launch, price erosion is often slower than after multiple generic entrants. Once several ANDA products are available, reimbursement pressure generally increases and branded market share can decline sharply.

Key Takeaways

• Collegium v. Teva involved Teva’s ANDA for generic Xtampza ER extended-release oxycodone.
• The dispute focused on Collegium’s DETERx abuse-deterrent formulation technology.
• The principal patents associated with the case included U.S. Patent Nos. 9,693,961 and 9,737,530.
• Collegium pursued Hatch-Waxman infringement claims based on Teva’s Paragraph IV certifications.
• The case ended through settlement and dismissal rather than a reported final trial judgment.
• The settlement reduced immediate litigation uncertainty but made the agreed generic launch date the central commercial issue.
• Xtampza ER is a small-molecule drug. Biosimilar risk is not applicable.
• The patent estate is strongest against direct copies and weaker against materially redesigned extended-release oxycodone formulations.
• Future generic risk depends on Teva’s settlement rights, other ANDA filers, Orange Book patent expiry and the ability of competitors to design around the DETERx claims.

FAQs

Does Teva have FDA approval for generic Xtampza ER?

An ANDA filing and Paragraph IV litigation do not establish final FDA approval. Approval depends on FDA review, patent-related regulatory restrictions and any settlement limitations.

Are Xtampza ER patents composition patents or formulation patents?

The commercially relevant patents are primarily formulation and drug-product patents covering controlled-release oxycodone dosage forms and abuse-deterrent characteristics.

Can a generic company avoid Collegium’s patents by changing excipients?

Potentially. A redesigned product may avoid literal infringement, but it must still meet FDA bioequivalence requirements and may face the doctrine of equivalents.

Does the Teva settlement eliminate all Collegium patent rights?

No. Settlement of one ANDA case does not eliminate the patent estate or determine the outcome of separate disputes involving other generic applicants.

Is a biosimilar pathway available for Xtampza ER?

No. Xtampza ER is a small-molecule oxycodone product regulated through the generic-drug framework, not the biologics and biosimilars framework.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
2. U.S. District Court for the District of Delaware. (2018). Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc., No. 1:18-cv-01900.
3. Collegium Pharmaceutical, Inc. (2019-2024). Annual reports on Form 10-K. U.S. Securities and Exchange Commission.
4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 9,693,961 and 9,737,530.
5. U.S. Food and Drug Administration. (2016). Xtampza ER approval and prescribing information.